EP1879590A1 — Eslicarbazepine acetate and methods of use
Assigned to Bial Portela and Cia SA · Expires 2008-01-23 · 18y expired
What this patent protects
The present disclosure relates to the treatment of various diseases and conditions like affective disorders, schizoaffective disorders, bipolar disorders, attention disorders, anxiety disorders, neuropathic pain and neuropathic pain-related disorders, sensorimotor disorders, vest…
USPTO Abstract
The present disclosure relates to the treatment of various diseases and conditions like affective disorders, schizoaffective disorders, bipolar disorders, attention disorders, anxiety disorders, neuropathic pain and neuropathic pain-related disorders, sensorimotor disorders, vestibular disorders, or nervous function alternations in degenerative and post-ischemic diseases, etc…, with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.
Drugs covered by this patent
- Aptiom (ESLICARBAZEPINE ACETATE) · Sumitomo Pharma Am
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.